Significant Intracranial Response and Long-term Survival after Pembrolizumab in Non-small Cell Lung Cancer Brain Metastases Resistant to Stereotactic Radiotherapy

Brain metastases from non-small cell lung cancer are typically managed with local therapies, such as surgery and radiotherapy, whereas systemic treatments have historically demonstrated limited efficacy in the intracranial setting. Immune checkpoint inhibitors, particularly programmed cell death-1 inhibitors, have recently demonstrated potential in this context. We report a case of a 48-year-old man with lung adenocarcinoma who developed a radiation-resistant brain metastasis with postoperative recurrence and severe neurological deterioration. Despite multiple courses of stereotactic radiosurgery and surgical resection, the lesion progressed, accompanied by seizures, impaired consciousness, and poor performance status.

Authors

Institutions

Publication Details

Journal
NMC Case Report Journal
Published
2026-08-24
DOI
https://doi.org/10.2176/jns-nmc.2026-0128
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Significant Intracranial Response and Long-term Survival after Pembrolizumab in Non-small Cell Lung Cancer Brain Metastases Resistant to Stereotactic Radiotherapy

Atsuya Akabane, Teppei Morikawa, Ryuichi Noda, Akihiro Shimoi et al.
NMC Case Report Journal
Brain Metastases and Treatment
article

Significant Intracranial Response and Long-term Survival after Pembrolizumab in Non-small Cell Lung Cancer Brain Metastases Resistant to Stereotactic Radiotherapy

Atsuya Akabane, Teppei Morikawa, Ryuichi Noda, Akihiro Shimoi, Kazuhiro Usui, Masafumi Segawa, Tomohiro Inoue, Mariko Kawashima, Yoshio MASUDA
article en

Abstract

Brain metastases from non-small cell lung cancer are typically managed with local therapies, such as surgery and radiotherapy, whereas systemic treatments have historically demonstrated limited efficacy in the intracranial setting. Immune checkpoint inhibitors, particularly programmed cell death-1 inhibitors, have recently demonstrated potential in this context. We report a case of a 48-year-old man with lung adenocarcinoma who developed a radiation-resistant brain metastasis with postoperative recurrence and severe neurological deterioration. Despite multiple courses of stereotactic radiosurgery and surgical resection, the lesion progressed, accompanied by seizures, impaired consciousness, and poor performance status.

NMC Case Report JournalVol. 13(0)
NTT Medical Center (JP)
Good health and well-being
Openalex Percentile: Top 11%
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Significant Intracranial Response and Long-term Survival after Pembrolizumab in Non-small Cell Lung Cancer Brain Metastases Resistant to Stereotactic Radiotherapy — Atsuya Akabane, Teppei Morikawa, et al. · NMC Case Report Journal (2026) | TGRS Research Map | TGRS